Related Experiment Videos
Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy
1Department of Neurology, University of Rochester, New York, USA. jlangfitt@mail.neurology.rochester.edu
Epilepsia
|February 1, 1997
Summary
Anterotemporal lobectomy (ATL) for epilepsy is cost-effective, with a marginal cost-effectiveness ratio of $15,581 per quality-adjusted life year (QALY). This high-cost epilepsy treatment offers value comparable to other health technologies.
Area of Science:
- Health Economics
- Neurosurgery
- Epilepsy Management
Background:
- High-cost health technologies necessitate scrutiny for efficient resource allocation.
- Understanding the cost-effectiveness of advanced epilepsy treatments is crucial.
Purpose of the Study:
- To estimate the cost-effectiveness of anterotemporal lobectomy (ATL) versus standard medical management for medically-intractable epilepsy.
- To inform resource allocation decisions for high-technology epilepsy care.
Main Methods:
- Decision analysis modeling was employed.
- Local cost data from Rochester, NY, were integrated into a lifetime cost-outcome model.
- The model assessed evaluation, ATL, and follow-up costs and outcomes.
Main Results:
- The base case analysis indicated a marginal cost-effectiveness ratio (MECR) of $15,581 per quality-adjusted life year (QALY).
- Sensitivity analyses revealed scenarios where ATL evaluation was dominant or potentially not cost-effective (MCER > $50,000/QALY).
Conclusions:
- ATL cost-effectiveness estimates are within an acceptable range, considering parameter uncertainties.
- ATL's cost-effectiveness favorably compares with other health technologies.
- Further multicenter studies are needed to refine estimates regarding regional variations, long-term outcomes, and quality of life impacts.